rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

David Shapiro

Director

Company insider

Files Form 4 as: Director, Design Therapeutics; Director, Damora Therapeutics; Director, VivoSim Labs; Chief Medical Officer, Intercept Pharmaceuticals.

Every Form 4 they filed

In numbers

Trades disclosed
346
Buys
0
Sells
75
Bought
$0
Sold
$37.1M
Companies
4
Companies where not an officer
3
First trade
9 Apr 2012
Last trade
9 Jun 2026
Last filed
11 Jun 2026

Companies traded

Where they are an officer
Intercept PharmaceuticalsOfficer · last 1 May 20190 buys · 75 sells
Everywhere else they filed: board seats, 10% stakes, other companies
DSGN Design TherapeuticsDirector · Biotechnology · last 9 Jun 20260 buys · 0 sells
DMRA Damora TherapeuticsDirector · Biotechnology · last 18 Jun 20250 buys · 0 sells
VIVS VivoSim LabsDirector · Biotechnology · last 5 Sep 20190 buys · 0 sells

Activity over time

1 Nov 2024 – 1 Oct 2026
101Nov 24May 25Nov 25Apr 26Oct 26

Buys above the line, sells below, each month.

Every trade

TradedCompanyWhatAmount
9 Jun 2026filed 11 Jun 2026DSGN Design Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—30,000 at $0.00filing
9 Jun 2026filed 11 Jun 2026DSGN Design Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—30,000 at $0.00filing
31 Mar 2026filed 1 Apr 2026DSGN Design Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—60,000 at $0.00filing
31 Mar 2026filed 1 Apr 2026DSGN Design Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—7,500 at $0.00filing
31 Mar 2026filed 1 Apr 2026DSGN Design Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—60,000 at $0.00filing
31 Mar 2026filed 1 Apr 2026DSGN Design Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—7,500 at $0.00filing
18 Jun 2025filed 20 Jun 2025DMRA Damora Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—720 at $0.00filing
20 Jun 2024filed 21 Jun 2024DMRA Damora Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—18,000 at $0.00filing
14 Jun 2023filed 15 Jun 2023DMRA Damora Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—18,000 at $0.00filing
14 Jun 2022filed 15 Jun 2022DMRA Damora Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—18,000 at $0.00filing
5 Sep 2019filed 9 Sep 2019VIVS VivoSim Labsoption or derivative · BiotechnologySEC FORM 4 Code A—52,000 at $0.00filing
1 May 2019filed 3 May 2019Intercept Pharmaceuticalsoption or derivativeSEC FORM 4 Code M—2,000 at $0.00filing
1 May 2019filed 3 May 2019Intercept PharmaceuticalsSEC FORM 4 Code M$64K2,000 at $31.90filing
1 May 2019filed 3 May 2019Intercept PharmaceuticalsSEC FORM 4 Sold$173K2,000 at $86.28filing
15 Apr 2019filed 16 Apr 2019Intercept Pharmaceuticalsoption or derivativeSEC FORM 4 Code M—2,000 at $0.00filing
15 Apr 2019filed 16 Apr 2019Intercept PharmaceuticalsSEC FORM 4 Code M$64K2,000 at $31.90filing
15 Apr 2019filed 16 Apr 2019Intercept PharmaceuticalsSEC FORM 4 Sold$190K2,000 at $95.00filing
3 Apr 2019filed 3 Apr 2019Intercept PharmaceuticalsSEC FORM 4 Sold$65K562 at $115.01filing
1 Apr 2019filed 3 Apr 2019Intercept PharmaceuticalsSEC FORM 4 Code F$54K482 at $111.50filing
1 Mar 2019filed 1 Mar 2019Intercept Pharmaceuticalsoption or derivativeSEC FORM 4 Code M—2,000 at $0.00filing

News

David Shapiro: 'It's ideology, not regulation'biznews.com · 10 Sep 2026

1 headline in the last 90 days name David Shapiro; no company of theirs resolves to a name we track.

Sectors

Not placed75

Buys in green, sells in red, by the company’s sector.

Related people

Nobody else traded the same names lately.